Group items tagged

Pulmonary Arterial Hypertension (PAH) is a disease that affects the vasculature of the heart, specifically the arteries that transport blood from the heart to the lungs. Common symptoms include heart palpitations or an irregular rhythm, chest pain, coughing, wheezing, shortness of breath, chest discomfort when breathing, and sometimes even heart failure. The cause of pulmonary hypertension is not known, but research has indicated that genetic and hormonal factors may play a role in its development. The growing prevalence of Pulmonary Arterial Hypertension (PAH) is driving the growth of the Pulmonary Arterial Hypertension (PAH) Market. According to the European Respiratory Society, PAH is a rare disease, with an estimated prevalence ranging from 10 to 52 cases per million. The growing geriatric population is again increasing the prevalence of such disease which is also projected to foster the growth of the Pulmonary Arterial Hypertension (PAH) market. According to the United nation, by 2050, one in six people in the world will be over age 65 (16%), up from one in 11 in 2019 (9%). By 2050, one in four persons living in Europe and Northern America could be aged 65 or over. North America is projected to gain significant growth over the forecast period and this is attributed to the growing adoption of advanced treatment for treating pulmonary arterial hypertension. Moreover, increasing spending by the government on the healthcare sector is again augmenting the regional market growth. According to the U.S. Centers for Medicare & Medicaid Services, National health spending is projected to grow at an average annual rate of 5.4 percent for 2019-28 and to reach $6.2 trillion by 2028. Reads more @ https://coherentmarketinsights-blog.blogspot.com/2021/02/increasing-global-healthcare-spending.html

Platelet-rich plasma is a coagulated blood-rich polymer, made from extracted platelets. Extracted platelets are normally coagulated by monocytes or lymphocytes with fibrin. Platelets are also commonly injected into the body's bloodstream to support tissue healing following tissue surgery. Platelet-rich plasma has been found effective against bleeding disorders. It also helps reduce the risk of deep vein thrombosis (DVT) in patients with high blood pressure and in those taking anticoagulants. It may also reduce the risk of pulmonary embolism (PE), which is blood clots that enter the lungs and pulmonary system. In the chest, the clot can stop or limit the flow of blood to the heart. PE often leads to cardiac arrest and death. Increasing cosmetic surgeries is expected to drive growth of the global platelet rich plasma market during the forecast period. Cosmetic surgeries refer to surgical specialty involving the restoration, alteration, or reconstruction of the human body. According to the International Society of Aesthetic Plastic Surgery (ISAPS), in 2018, around 128,398 cosmetic procedures in Thailand and 1,036,618 procedures in Mexico were carried out. Hence, these factors are expected to drive growth of the global platelet rich plasma market during the forecast period. Furthermore, increasing prevalence of cosmetic surgeries is expected to boost the global platelet rich plasma market growth over the forecast period. Read more @ https://sachinbhombe.blogspot.com/2021/03/platelet-rich-plasma-market-is-witness.html

Approximately 2 billion people suffer from Tuberculosis each year. Tuberculosis or simply TB is an infectious and highly contagious disease of the body especially lungs. It spreads mainly via Mycobacterium tuberculosis which is a tough and highly resistant microbe.

Tuberculosis is a serious, infectious and often fatal disease of the lungs. It can also affect other parts of the body. But the most common type of Tuberculosis is pulmonary Tuberculosis. It is more common in women than in men. The causative agent is a Gram-positive bacterium (Mycobacterium tuberculosis).